Impact of Hormone receptor status on recurrence in HER2+ bc
 

http://breast-cancer-research.com/co...df/bcr3324.pdf

"Concordant with previous knowledge, trastuzumab increases the rates of survival independently of HR status. After stratifying by adjuvant trastuzumab use, the differences in survival by HR status persisted. It is worth noting that despite a lower rate of pathologic complete responses (pCR) among patients with HR+/HER2+ tumors across neoadjuvant trials [10, 39-45], the overall prognosis of such patients is not worse than those with HR-/HER2+ tumors. These findings also suggest that in patients with HR+/HER2+ tumors, lack of pCR will, potentially, have less prognostic value than among patients with HR-/HER2+ tumors [46]."

Hopeful

Re: Impact of Hormone receptor status on recurrence in HER2+ bc
 

Interesting. Thx, Hopeful.